A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants
-
By
-
Rina Su
-
Rigonggaowa A
-
Fang Yao
-
Yanbin An
-
Cheng Cai
-
Lei Yun
-
July 8, 2026
-
Clinical Scorecard: An Observational Study on the Use of Nirsevimab for RSV Infection Prevention in Preterm Infants at a Single Center
At a Glance
| Category | Detail |
|---|
| Condition | Respiratory Syncytial Virus (RSV) Infection |
| Key Mechanisms | Nirsevimab is a monoclonal antibody that targets the RSV fusion protein, blocking viral entry into host cells. |
| Target Population | Preterm infants with gestational age less than 37 weeks. |
| Care Setting | Neonatology Department of Inner Mongolia Maternity and Child Health Care Hospital |
Key Highlights
- Nirsevimab significantly reduced RSV-associated respiratory infections (98.73% efficacy vs. 84.81%).
- No rehospitalization was required in the nirsevimab immunized group.
- Adverse reactions were not observed in the immunized group.
Guideline-Based Recommendations
Diagnosis
- RSV infection should be diagnosed based on clinical presentation and confirmed with appropriate testing.
Management
- Nirsevimab is recommended for preterm infants during the RSV season to prevent RSV infections.
Monitoring & Follow-up
- Monitor for RSV infection symptoms and potential adverse reactions post-nirsevimab administration.
Risks
- Preterm infants are at higher risk for severe RSV infections and associated complications.
Patient & Prescribing Data
Preterm infants, particularly those with low birth weight or congenital heart conditions.
Nirsevimab provides passive immunization and is effective in preventing RSV-related lower respiratory tract infections.
Clinical Best Practices
- Administer nirsevimab during the RSV season for at-risk preterm infants.
- Provide standard care including respiratory and nutritional support.
Related Resources & Content
